Growth Report: Pre-Clinical CROs Market Worth $8.41 Billion, Worldwide Driven by Increasing Number of Clinical Trials During (2019-2027) | The Insight Partners
June 29, 2023 09:20 ET | The Insight Partners
Pune, India, June 29, 2023 (GLOBE NEWSWIRE) -- The Insight Partners’ latest study on "Pre Clinical CROs Market Size Report, Forecast to 2027 – COVID-19 Impact and Global Analysis – by Service, End...
HPQ Silica Polvere Inc. signe un accord de non-divulgation avec un important fabricant de silice pyrogénée
May 25, 2023 08:00 ET | Ressources HPQ Silicium inc.
MONTRÉAL, 25 mai 2023 (GLOBE NEWSWIRE) -- HPQ Silicium inc. (« HPQ » ou « la Société ») (TSX-V: HPQ) (OTCQX: HPQFF) (FRA: O08), une entreprise technologique spécialisée dans les procédés...
HPQ Silica Polvere Inc. Signs Non-Disclosure Agreement With Leading Fumed Silica Manufacturer
May 25, 2023 08:00 ET | HPQ Silicon Inc.
MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ) (OTCQX: HPQFF) (FRA: O08), a technology company specializing in green engineering processes for...
Minerva logo
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
May 15, 2023 07:30 ET | Minerva Neurosciences, Inc
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva logo
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
May 10, 2023 08:00 ET | Minerva Neurosciences, Inc
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26,...
Arcutis logo.png
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023 16:02 ET | Arcutis Biotherapeutics, Inc.
Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarterContinued expansion of commercial...
Arcutis logo.png
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023 16:02 ET | Arcutis Biotherapeutics, Inc.
Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growthSecured expanded commercial...
Arcutis logo.png
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
February 21, 2023 08:00 ET | Arcutis Biotherapeutics, Inc.
Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam would be the first topical drug for seborrheic...
2019 logo_150x35_jpg.jpg
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
January 06, 2023 08:00 ET | Novan, Inc.
– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin infection that...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING LAW FIRM, Encourages Veru, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– VERU
December 24, 2022 15:58 ET | The Rosen Law Firm PA
WHY: NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Veru, Inc. (NASDAQ: VERU) between May 11, 2022 and...